Investors / United States / 3E Bioventures Capital
3E Bioventures Capital
Venture capital · Palo Alto, CA, United States · North America
3E Bioventures Capital is a life science focused venture capital fund that invests in health innovators. It invests in biotech, including new drugs, new modalities and drug discovery platforms, and in TechBio at the intersection of biology and technology.
Invests inHealthcare & Biotech
In its own wordsbiotechtechbiolife sciencesdrug discoveryhealthcare
Your fit with 3E Bioventures Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fits3E Bioventures Capital lists 24 checked portfolio companies on its own site and is named in 3 funding rounds. Its most frequent entry is Series A, 67% of the companies with a known first round. Its largest themes are Healthcare & Biotech (96%) and AI & Machine Learning (4%). 79% of its companies are based in United States. It invests most often alongside Plaisance Capital Management, ARCH Venture Partners and Asset Management Company.
Counts come from funding rounds that name 3E Bioventures Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not 3E Bioventures Capital's whole history. Rounds on record name 3 companies; its own site lists 24. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first round3E Bioventures Capital does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 67% |
| Series B | 33% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 3 | 0 |
| '26 | 0 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 59th | 24 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 82th | 13% of companies confirmed by a round |
| Sector focus | 97th | 96% in its largest sector |
| Reach | 69th | 4 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Plaisance Capital Management | 3 |
| ARCH Venture Partners | 2 |
| Asset Management Company | 2 |
| Atinum Investment | 2 |
| F-Prime Capital | 2 |
| RA Capital | 2 |
| StartX | 2 |
| +ND Capital | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers2396%
- No longer answers00%
- Points to another company14%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 96% | 15% |
| AI & Machine Learning | 4% | 18% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Plaisance Capital Management
Compare 3E Bioventures Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with 3E Bioventures Capital| Date | Company | Stage |
|---|---|---|
| 2 Oct 2025 | Series B | |
| 4 Sept 2025 | Series A | |
| 25 Aug 2025 | Series A |
Round details for 3E Bioventures Capital
Amounts, full round histories and every co-investor in 3E Bioventures Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
24 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Arnatar Therapeutics develops RNA medicines to treat various diseases, including cardiometabolic, liver, CNS, and kidney diseases. | Healthcare & Biotech | Aug 2025Series A | Page + round | |
| Avirmax is a preclinical stage biopharmaceutical company focusing on innovation and development of genetic medicines to treat chronic and degenerated ocular diseases. | Healthcare & Biotech | Portfolio page | ||
| C4 Therapeutics develops a new generation of medicine using targeted protein degradation to treat disease | Healthcare & Biotech | Portfolio page | ||
| The company develops therapies designed to help patients and caregivers living with age-related neurodegenerative diseases. | Healthcare & Biotech | Portfolio page | ||
| Cullgen builds protein degraders and Degrader-Antibody Conjugates for the treatment of cancer, pain and inflammatory diseases | Healthcare & Biotech | Portfolio page | ||
| Cytek Biosciences develops and sells flow cytometry systems and related products and services. | Healthcare & Biotech | Portfolio page | ||
| Dermaliq Therapeutics, Inc. develops breakthrough topical therapies and medical skin care products based on a proprietary technology platform, focusing on dermatology, particularly hair loss treatments. | Healthcare & Biotech | Portfolio page | ||
| Dewpoint Therapeutics develops first-in-class condensate modulator therapies for intractable targets, including cancer and ALS. | Healthcare & Biotech | Portfolio page | ||
| The company develops, produces, and sells point-of-care testing and health management products. | Healthcare & Biotech | Portfolio page | ||
| Genotix digitally characterizes and quantitates biomarkers at biological resolution to reveal early disease indicators. | Healthcare & Biotech | Portfolio page | ||
| Larkspur develops first-in-class protein degraders that target key stress-response pathways essential to tumor survival | Healthcare & Biotech | Portfolio page | ||
| Lipidio is developing a drug that utilizes skin signaling mechanisms to deliver systemic benefits including significant decreases in weight and total body fat. | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Myro Therapeutics develops oral small molecule therapies for central nervous system diseases | Healthcare & Biotech | Portfolio page | ||
| The company applies nanobiotechnology to aquaculture and develops innovative solutions for the industry | AI & Machine LearningHealthcare & Biotech | Portfolio page | ||
| OncoC4 develops first-in-class and best-in-class medicines for hard-to-treat cancer and Alzheimer’s disease | Healthcare & Biotech | Oct 2025Series B | Page + round | |
| Profusa develops and commercializes technologies for continuous, real-time monitoring of body chemistry, including tissue oxygen and glucose levels | Healthcare & Biotech | Portfolio page | ||
| ProNovo Therapeutics develops novel, precision therapeutics to address urgent unmet needs in the treatment of neuropsychiatric disorders | Healthcare & Biotech | Portfolio page | ||
| Quadriga BioSciences is developing a novel chemotherapeutic agent to treat cancer. | Healthcare & Biotech | Portfolio page | ||
| Rapafusyn is pioneering RapaGlues, a unique modality of non-degrading molecular glues for targets previously considered intractable | Healthcare & Biotech | Sept 2025Series A | Page + round |
About this data
site last read 8 Nov 2026- Site
- 3ebiovc.com
- Last read
- 8 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 25 Aug 2025
- Companies checked
- 24
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get 3E Bioventures Capital's profile as data
Pull 3E Bioventures Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/3ebiovc.com
# also
GET /v1/firms/3ebiovc.com/portfolio
GET /v1/firms/3ebiovc.com/coinvestors
GET /v1/firms/3ebiovc.com/news